Compare WLDS & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDS | PFSA |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 8.9M |
| IPO Year | 2022 | N/A |
| Metric | WLDS | PFSA |
|---|---|---|
| Price | $1.06 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 371.1K | ★ 60.3M |
| Earning Date | 03-09-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | $1.00 | $0.07 |
| 52 Week High | $11.40 | $12.76 |
| Indicator | WLDS | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 44.90 |
| Support Level | $1.08 | $0.09 |
| Resistance Level | $1.13 | $0.12 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 12.07 | 32.55 |
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.